GlassScriptPhysician profile
Linzi R Smith
NPI 1154002707
$949.14
in general payments reported to CMS, 2019-2025
17 companies · $574 in 2025
The $574 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $65.87 · 2024: $309 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.14 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $248.91 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Globus Medical, INC. | $94.27 | 2025 | Senza |
| Novo Nordisk INC | $81.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $78.01 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $75.94 | 2024-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $67.26 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.34 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $42.69 | 2024 | Trintellix |
| Lundbeck LLC | $35.88 | 2024 | Rexulti |
| Alkermes, INC. | $29.09 | 2023-2024 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.71 | 2024-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $19.77 | 2023 | Fanapt, Hetlioz |
| Dexcom, INC. | $18.78 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $18.75 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $16.87 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.77 | 2025 | |
| Amgen INC. | $14.54 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linzi Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.